The RANK–RANKL axis: an opportunity for drug repurposing in cancer?

@article{Peters2019TheRA,
  title={The RANK–RANKL axis: an opportunity for drug repurposing in cancer?},
  author={S. Peters and Philippe Cl{\'e}zardin and Iv{\'a}n M{\'a}rquez-Rodas and Daniela Niepel and Craig Gedye},
  journal={Clinical and Translational Oncology},
  year={2019},
  volume={21},
  pages={977-991}
}
Drug repurposing offers advantages over traditional drug development in terms of cost, speed and improved patient outcomes. The receptor activator of nuclear factor kappa B (RANK) ligand (RANKL) inhibitor denosumab is approved for the prevention of skeletal-related events in patients with advanced malignancies involving bone, including solid tumours and multiple myeloma. Following improved understanding of the role of RANK/RANKL in cancer biology, denosumab has already been repurposed as a… 
The Roadmap of RANKL/RANK Pathway in Cancer
TLDR
The pre-clinical and clinical evidence of the relevance of the RANKL/RANK pathway in cancer biology and therapeutics, focusing on bone metastatic disease, BCa onset and progression, and immune modulation is summarized and discussed.
Repurposing denosumab in breast cancer beyond prevention of skeletal related events: Could nonclinical data be translated into clinical practice?
TLDR
An overview of the therapeutic potential of denosumab in breast cancer beyond prevention of skeletal-related events (SREs), with focus on prevention of carcinogenesis in BRCA mutation carriers and on adjuvant treatment in early breast cancer patients is provided.
Repurposing denosumab in lung cancer beyond counteracting the skeletal related events: an intriguing perspective
TLDR
The present review presents the available preclinical and clinical data indicating that denosumab may provide survival benefit to lung cancer patients beyond the counteraction of SREs.
Dual targeting of RANKL and PD‐1 with a bispecific antibody improves anti‐tumor immunity
TLDR
A novel bispecific antibody (BsAb) co‐targeting RANKL and PD‐1 is developed that increases the overall response rate relative to ICI treatment alone in patients with advanced melanoma and lung cancer.
RANK-RANKL Signaling in Cancer of the Uterine Cervix: A Review
TLDR
Abundant circumstantial evidence suggests that RANKL inhibition may (partially) reverse an immunosuppressive status and the use of denosumab, a monoclonal antibody directed to RankL, as an immunomodulatory strategy is an attractive concept which should be further explored in combination with immune therapy in patients with cervical cancer.
RANKL regulates testicular cancer growth and Denosumab treatment has suppressive effects on GCNIS and advanced seminoma.
TLDR
This study shows that the RankL signalling system is expressed in GCNIS and seminoma where RANKL inhibition suppresses tumour growth in vitro and in vivo.
The safety profile of denosumab in oncology beyond the safety of denosumab as an anti-osteoporotic agent: still more to learn
TLDR
An overview of the adverse events of denosumab in oncology is provided, with a focus on hypocalcemia, medication-related osteonecrosis of the jaw, atypical femoral fracture(s), post-denosumAB vertebral fractures, increased risk of infections, and excess of second primary cancer.
RANKL biology: bone metabolism, the immune system, and beyond
TLDR
The current understanding of the functions of the RANKL/RANK/OPG system in biological processes is summarized.
Level of Some Biomarkers of Bone Remodeling in Treated Multiple Myeloma Patients and Compered with New Diagnostic Multiple Myeloma Patients
TLDR
It appears that chemotherapy reduces resorption in treated myeloma patients, and RANKL, OPG and IL-6 play significant roles in MM pathophysiology, as regulators of bone turnover.
...
...

References

SHOWING 1-10 OF 127 REFERENCES
Effects of RANKL-Targeted Therapy in Immunity and Cancer
TLDR
The role of RANKL/RANK in bone, immunity, and cancer is reviewed and the potential effects of routine treatment with denosumab beyond the bone represents an important area of investigation.
The RANK/RANKL/OPG system in tumorigenesis and metastasis of cancer stem cell: potential targets for anticancer therapy
TLDR
This review aimed to summarize several original and up-to-date articles focusing on the role of this signaling system in cancer cell development and metastasis as well as potential therapeutic agents targeting any of the three tumor necrotic factor super family proteins and/or their downstream signaling pathways.
RANK as a therapeutic target in cancer
TLDR
The main functions of RANK signaling in bone remodeling, immune cells and epithelial differentiation are revisited and the mechanistic evidence that supports its pleiotropic effects on cancer is discussed.
Clinical prognostic significance and pro-metastatic activity of RANK/RANKL via the AKT pathway in endometrial cancer
RANK/RANKL plays a key role in metastasis of certain malignant tumors, which makes it a promising target for developing novel therapeutic strategies for cancer. However, the prognostic value and
RANKL/RANK—beyond bones
TLDR
The recently emerging role of the RANKL/RANK signaling axis in mammary gland development, cancer metastasis, hormone-derived breast cancer development, and thermal regulation is summarized and the striking therapeutic potential of this pathway is highlighted.
Where Do Bone-Targeted Agents RANK in Breast Cancer Treatment?
TLDR
In a subgroup analysis of the negative Adjuvant Zoledronic Acid to Reduce Recurrence (AZURE) trial, the bisphosphonate zoledronic acid showed potential for improving survival in patients who were postmenopausal; however, a prospective study in this patient population is required to validate this observation.
...
...